Juvenile idiopathic arthritis treated with biological therapies by Maria Velloso Feijoo et al.
POSTER PRESENTATION Open Access
Juvenile idiopathic arthritis treated with
biological therapies
Maria Luisa Velloso Feijoo*, Rosalia Martinez Perez, Julia Uceda Montañes, Jose Luis Marenco de la Fuente
From 7th European Workshop on Immune-Mediated Inflammatory Diseases
Noordwijk aan Zee, the Netherlands. 28-30 November 2012
Background
Biological therapies have dramatically changed the prog-
nosis for children with juvenile idiopathic arthritis (JIA).
There are doubts about the possibility of discontinuing
treatment once remission is achieved. We focus in this
question in our series.
Objective
To assess the efficacy and safety of these drugs in our
series of patients with JIA.
Materials and methods
We identified 9 children with JIA treated with biologic
therapies, and we made a description of our experience.
Results
The mean age was 14.55 ± 5.85, with a female predomi-
nance (66.7%). At diagnosis, mean age was 4.94 ± 2.9, and
at the beginning of biological treatment of 8.77 ± 2.63.
The median time from diagnosis to initiation of biological
therapy was 3.94 ± 2.83 years. The disease characteristics
are detailed in the table.
All the children had previously received DMARDs
(66.6% methotrexate (MTX) and 33.3% MTX and sulfa-
salazine). Eight of the 9 patients (88.9%) were taking
corticosteroids at baseline. Eight received etanercept
(ETN) and one Adalimumab (ADA), with good out-
comes in all the patients unless 1 that had to switch
from ETN to ADA due to inefficacy, and improved after
the change. The steroids were suspended in 75% of chil-
dren (6). Differences between mean values of CRP, ESR,
and platelets from baseline to actual moment were sta-
tistically significant.
The median biologic time is 4 (1.11) years.
Actually all the children are in remission, two of them
(patients 1 and 4) without biological treatment or classic
DMARDs (since 5 and 2 years respectively).
None of the children have had significant adverse
effects nor required hospitalization from the beginning
of therapy.
Rheumatology Unit, Valme University Hospital, Seville, Spain
Table 1
Patient Sex Age Type RF ANA Uveitis Swollen joints
1 Female 10 Systemic Negative Positive No Knee
2 Female 13 Polyarticular Negative Negative No Knee and wrists
3 Male 10 Systemic Positive Positive No Knee and wrists
4 Female 10 Polyarticular Negative Negative No Temporomandibular and wrists
5 Female 11 Polyarticular Negative Negative No Wrists and metatarsophalangeal
6 Male 7 Oligoarticular Negative Negative No Ankles
7 Male 7 Oligoarticular Negative Negative No Knees
8 Female 5 Oligoarticular Negative Positive Yes Knees
9 Female 6 Oligoarticular Negative Negative No Ankles
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Discussion
ETN has proved its efficacy in JIA (regardless of the type
of onset), as it has been reported in multiple efficacy and
safety studies, including long term studies of up to eight
years of continuous therapy.
We present our experience in children treated with up
to 11 years, with good outcomes in terms of efficacy and
safety in all the patients, and also 2 patients still in remis-
sion after 2 and 5 years without treatment.
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